[{"address1": "175 Innovation Boulevard", "city": "Wilmington", "state": "DE", "zip": "19805", "country": "United States", "phone": "302 467 1280", "website": "https://preludetx.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.", "fullTimeEmployees": 128, "companyOfficers": [{"maxAge": 1, "name": "Dr. Krishna  Vaddi D.V.M., Ph.D.", "age": 57, "title": "Founder, CEO & Director", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 905916, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Edna  Huang M.D.", "age": 50, "title": "President & Chief Medical Officer", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 865629, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bryant David Lim J.D.", "age": 52, "title": "Interim CFO, Chief Legal Officer & Corporate Secretary", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 586425, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Aimee  Crombie Ph.D.", "title": "Senior VP and Head of Strategic Planning & Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Madhu  Pudipeddi Ph.D.", "title": "Senior Vice President of Technical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Peggy A. Scherle Ph.D.", "age": 61, "title": "Chief Scientific Officer", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 868617, "exercisedValue": 0, "unexercisedValue": 436567}, {"maxAge": 1, "name": "Lindsey  Trickett", "title": "Vice President of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Michele  Porreca M.B.A.", "title": "Chief People Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Andrew P. Combs Ph.D.", "age": 56, "title": "Executive VP & Chief Chemistry Officer", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 562461, "exercisedValue": 0, "unexercisedValue": 399432}, {"maxAge": 1, "name": "Mr. Naveen  Babbar Ph.D.", "title": "Senior Vice President of Translation Medicine", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 6, "compensationRisk": 9, "shareHolderRightsRisk": 10, "overallRisk": 9, "governanceEpochDate": 1726617600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.55, "open": 2.55, "dayLow": 2.4501, "dayHigh": 2.65, "regularMarketPreviousClose": 2.55, "regularMarketOpen": 2.55, "regularMarketDayLow": 2.4501, "regularMarketDayHigh": 2.65, "beta": 1.516, "forwardPE": -1.59375, "volume": 469059, "regularMarketVolume": 469059, "averageVolume": 260447, "averageVolume10days": 664880, "averageDailyVolume10Day": 664880, "bid": 2.48, "ask": 2.6, "bidSize": 200, "askSize": 300, "marketCap": 140312480, "fiftyTwoWeekLow": 1.66, "fiftyTwoWeekHigh": 6.8, "fiftyDayAverage": 5.0831, "twoHundredDayAverage": 4.2283, "currency": "USD", "enterpriseValue": -21327602, "floatShares": 13736859, "sharesOutstanding": 42174200, "sharesShort": 2433584, "sharesShortPriorMonth": 771279, "sharesShortPreviousMonthDate": 1722384000, "dateShortInterest": 1724976000, "sharesPercentSharesOut": 0.0442, "heldPercentInsiders": 0.09064999, "heldPercentInstitutions": 0.94105005, "shortRatio": 12.88, "shortPercentOfFloat": 0.14039999, "bookValue": 3.314, "priceToBook": 0.7694629, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -129854000, "trailingEps": -1.77, "forwardEps": -1.6, "pegRatio": -0.05, "enterpriseToEbitda": 0.151, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "PRLD", "underlyingSymbol": "PRLD", "shortName": "Prelude Therapeutics Incorporat", "longName": "Prelude Therapeutics Incorporated", "firstTradeDateEpochUtc": 1601040600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "b4d5f445-4c0f-32e5-9fdb-a86b330519d9", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.55, "targetHighPrice": 10.0, "targetLowPrice": 3.0, "targetMeanPrice": 5.8, "targetMedianPrice": 5.0, "recommendationMean": 2.6, "recommendationKey": "hold", "numberOfAnalystOpinions": 5, "totalCash": 179844000, "totalCashPerShare": 3.268, "ebitda": -140783008, "totalDebt": 18204000, "quickRatio": 7.707, "currentRatio": 7.83, "debtToEquity": 9.987, "returnOnAssets": -0.35222, "returnOnEquity": -0.58449, "freeCashflow": -56832376, "operatingCashflow": -104109000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-23"}]